7.1. localised low-risk disease. 7.1.1. general considerations kidney-sparing surgery kidney-sparing surgery low-risk utuc reduces morbidity associated radical nephroureterectomy (e.g., loss kidney function), without compromising oncological outcomes . low-risk cancers, preferred approach survival similar rnu . option therefore discussed low-risk cases, irrespective status contralateral kidney, shared-decision making process patient. recommendations kidney-sparing management utuc listed section 7.1.7. 7.1.2. ureteroscopy endoscopic ablation considered patients clinically low-risk cancer . flexible ureteroscope useful management pelvicalyceal tumours . patient informed need willing able comply early second-look urs stringent surveillance; complete tumour resection destruction necessary . nevertheless, risk disease progression remains endoscopic management due suboptimal performance imaging biopsy risk stratification tumour biology . systematic review reported comparable survival outcomes endoscopic treatment radical nephroureterectomy cost higher local recurrence rates repeated interventions, also uncertainties long-term renal preservation endoscopic treatment . 7.1.3. percutaneous access percutaneous management considered low-risk utuc renal pelvis . may also offered low-risk tumours lower caliceal system inaccessible difficult manage flexible urs. however, approach used less due availability improved endoscopic tools distal-tip deflection recent ureteroscopes . moreover, risk tumour seeding remains percutaneous access . 7.1.4. ureteral resection segmental ureteral resection adequate margins provides sufficient pathological specimens staging grading preserving ipsilateral kidney. segmental resection proximal two-thirds ureter associated higher failure rates distal ureter . distal ureterectomy ureteroneocystostomy indicated low-risk tumours distal ureter cannot completely removed endoscopically . total ureterectomy ileal-ureteral substitution renal autotransplantation pyelocystostomy technically feasible, selected cases renal-sparing procedure mandatory tumour low risk . 7.1.5. chemo-ablation single-arm phase iii trial including 71 patients biopsy-proven low-grade utuc less 15 mm showed use mitomycin-containing reverse thermal gel (ugn-101) instillations (6 weekly induction) chemoablation setting via retrograde catheter renal pelvis calyces associated complete response rate total 41 patients (58%) . frequently reported all-cause adverse events (aes) were: ureteric stenosis 31 (44%), urinary tract infection 23 (32%), haematuria 22 (31%), flank pain 21 (30%), nausea 17 (24%) 19/31 (61%) reported ureteric stenosis requiring treatment. among 41 patients complete response, 29 received least one maintenance instillation (median 6), 23/41 (56%) remained disease free one year . 7.1.6. adjuvant instillations 7.1.6.1. upper urinary tract antegrade instillation bcg mitomycin c upper urinary tract via percutaneous nephrostomy complete tumour eradication studied cis kidney-sparing management . retrograde instillation single-j open-ended ureteric stent also used. antegrade retrograde approach nephro-ureterogram needs rule ureteric obstruction leakage, asses infection ensure low pressure system avoid pyelovenous influx instillation/perfusion. reflux obtained double-j stent used approach suboptimal drug often reach renal pelvis [223-226]. systematic review meta-analysis assessing oncologic outcomes patients papillary utuc cis upper tract treated kidney-sparing surgery adjuvant endocavitary treatment analysed effect adjuvant therapies (i.e., chemotherapeutic agents and/or immunotherapy bcg) kidney- sparing surgery papillary non-invasive (taâ€“t1) utucs bcg treatment upper tract cis, finding difference method drug administration (antegrade vs. retrograde vs. combined approach) terms recurrence, progression, css, os; however, included studies underpowered highly heterogeneous. furthermore, recurrence rates following adjuvant instillations comparable reported literature untreated patients, questioning efficacy . analyses based retrospective small studies suffering publication reporting bias. recent evidence suggests early single adjuvant intracavitary upper tract instillation mitomycin c patients low-grade utuc might reduce risk local recurrence . authors report limited complications related instillations propose retrograde pyelography instillations commenced exclude contrast extravasation. concept need evaluation randomised context . 7.1.6.2. bladder currently data support use bladder instillation chemotherapy kidney-sparing surgery available rcts included patients received rnu. 7.1.7. recommendation kidney-sparing management localised low-risk utuc recommendationstrength ratingoffer kidney-sparing management primary treatment option patients low-risk tumours.strong